WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, a Massachusetts-based biotechnology research company, today announced that the US Food and Drug Administration (FDA) has approved the first phase of a biomarker discovery project to be conducted under a Cooperative Research and Development Agreement (CRADA) with the FDA’s National Center for Toxicological Research (NCTR). As part of FDA’s Critical Path Initiative, the Liver Toxicity Biomarker Study (LTBS) aims to discover biomarkers of human hepatotoxicity in the standard pre-clinical test used by pharmaceutical companies in the initial stages of drug development.
